Address: Suite 301, Building 2
169 Mengzi Road
Shanghai, 200032 P.R. China
Tel: +86(21) 53022951
Web: http://www.gbipharma.com/
Gbipharma.com is an information, business intelligence, and consulting company which has been servicing the pharmaceutical, biotechnology, and healthcare sectors, as well as investors and other financial and consulting service providers since 2002. We aim to provide a total information solution for companies within or intending to enter China’s market.
Gbipharma.com’s content and tools are targeted at individuals within marketing, business development, R&D, and operations functions up through top country and regional management levels. Our information products include the “China Pharmaceutical & Biotechnology Monthly”, the definitive English-language publication covering China’s pharma and healthcare sectors, and SOURCE, the ultimate (bilingual) information database service for pharmaceuticals in China.
GBI’s content has been created through rigorous primary and secondary research. Information is not easy to collect in China, and much misinformation exists. (Even publicly available data may be hard to compile, poorly organized, and non-standard, often rendering the information essentially unusable in its raw forms.) GBI’s analysts and managers have extensive experience in China’s pharmaceutical and healthcare sectors and are committed to creating meaningful, timely, and actionable information for their clients.
Information Services, Consulting
Dr Piers Ingram, PhD, co-founder, and CEO of Singapore-based biotech Hummingbird Bioscience, shares his motivation for establishing the company in 2015, their proprietary Rational Antibody Discovery (RAD) technology platform, and…
Dr Chengbin Wu, founder and CEO of EpimAb Biotherapeutics, introduces their exciting and proprietary bispecific antibody-generating platform, Fabs-In-Tandem Immunoglobulin (FIT-Ig®) and its ability to discover and generate novel and differentiated…
Zhenkun Ma, founder and CEO of TenNor Therapeutics, shares his cross-sectorial experiences in Big Pharma, biotech and non-profit organization that led to the establishment of TenNor Therapeutics; their mission to…
The US FDA has granted orphan drug designation to Shanghai-headquartered biotech CARsgen Therapeutics’ CAR-T cell therapy CT053 for multiple myeloma after positive results were observed in the phase I trial…
Competition is heating up among Asian stock exchanges hoping to lure the hottest prospects in Chinese biotech to list there. The newest competitor, Shanghai’s STAR Board, has already attracted over…
Earlier this year, PharmaBoardroom highlighted five of the most innovative and important biotech companies making waves in the world’s second-largest pharmaceutical market, China. Here, we pick out five more firms looking…
Dr Kai Lamottke, co-founder and MD of Bicoll GmbH, Munich, and since 2001, GM and board member of Bicoll Biotechnology (Shanghai) Co. Ltd discusses Bicoll’s presence in both the Chinese…
Jim Xu, GM of Medidata China, shares the importance of the China market to Medidata Solutions, the global leader in cloud services and solutions to the life sciences industry; his…
Dr. Chris Lu, CEO and cofounder of Laekna Therapeutics, shares Laekna’s ambition to deliver cures and improve the quality of life of patients globally, captured by the word ‘Laekna’, which…
Tony Acciarito, President of Thermo Fisher Scientific China, explains how he is delivering the company’s mission of ‘enabling our customers to make the world healthier, cleaner and safer’ in China,…
Zheru Zhang and Jielun Zhu of I-Mab Biopharma, shares their vision for the ambitious biotech company looking to develop their dual-pronged strategy of in-licensing ‘fast-to-market’ assets for their China portfolio…
Junshi Biosciences is an innovation-driven biopharmaceutical company with a focus on discovery and innovative drugs. Dr Li Ning, CEO, discusses being the first Chinese company to successfully launch a domestically-developed…
Kai Zhang, founder and chairman, and Sonia Wang, CEO, of Chinese respiratory technology specialist Omni Pharmaceuticals, discuss the respiratory market in China, how Omni plans to introduce four respiratory drugs…
Transcenta’s Xueming Qian outlines the new company’s origins, the space it seeks to fill within the highly competitive Chinese oncology market, and where Chinese biotech stands globally in 2019. …
See our Cookie Privacy Policy Here
